Bladder Cancer News and Research RSS Feed - Bladder Cancer News and Research

In North America, bladder cancer is the fourth most common cancer in men and in the top ten for women. In the United States, approximately 70,000 patients are newly diagnosed with bladder cancer each year. In addition, the cancers of many previously-diagnosed patients remain unresolved, sometimes leading to cystectomy (bladder removal) or death. Approximately 70% bladder cancer patients have the non-muscle-invasive form of bladder cancer at diagnosis.
Research shows alternative strategy to administer antibody-based immunotherapy for bladder cancer

Research shows alternative strategy to administer antibody-based immunotherapy for bladder cancer

Antibody-based immunotherapy is a new promising method to treat cancer. Unfortunately, today's treatments can result in adverse side effects. [More]
Purdue University biochemist develops novel method for identifying cancer biomarkers

Purdue University biochemist develops novel method for identifying cancer biomarkers

A Purdue University biochemist has developed a novel method for detecting certain types of proteins that serve as indicators for cancer and other diseases. [More]
Vitamin D deficiency may increase risk of developing bladder cancer

Vitamin D deficiency may increase risk of developing bladder cancer

Vitamin D deficiency is associated with an increased risk of developing bladder cancer, according to a systematic review of seven studies presented today at the Society for Endocrinology annual conference in Brighton. [More]
New Penn Medicine study raises questions about NLR as biomarker for bladder cancer

New Penn Medicine study raises questions about NLR as biomarker for bladder cancer

A blood test that has shown promise in predicting how cancer will progress and what treatments will be most effective for a given patient may not be reliable for either, according to a new Penn Medicine study published this week in Cancer, a peer-reviewed journal of the American Cancer Society. [More]
Basal tumor cell marker could help physicians personalize care for patients with bladder cancer

Basal tumor cell marker could help physicians personalize care for patients with bladder cancer

Tumor cells collected during the removal of a cancerous bladder and - in some cases - transplanted into mice with weakened immune systems, could help physicians rapidly identify high-risk cancers, determine prognosis and refine the use of biomarkers to personalize care for patients with this common cancer, according to a study published online on Oct. 24, 2016, in Scientific Reports. [More]
Chemotherapy leads to drug-resistance in bladder cancer patients

Chemotherapy leads to drug-resistance in bladder cancer patients

Chemotherapy is indicated as the first line of treatment for advanced bladder cancer. New research by Weill Cornell Medicine and University of Trento scientists shows that while chemotherapy kills the most common type of bladder cancer, urothelial cancer, chemotherapy also shapes the genetic evolution of remaining urothelial cancer cell clones to become drug-resistant. [More]
Cold medication could suppress spread of bladder cancers

Cold medication could suppress spread of bladder cancers

Hokkaido University researchers have discovered that a nonsteroid anti-inflammatory drug used for treating colds suppresses the spread of bladder cancers and reduces their chemoresistance in mice, raising hopes of a future cure for advanced bladder cancers. [More]
Study of pan-FGFR inhibitor uses mRNA in tumours to identify responders

Study of pan-FGFR inhibitor uses mRNA in tumours to identify responders

The first-in-human dose escalation study of the pan-FGFR (fibroblast growth factor receptor) inhibitor BAY 1163877 in patients with treatment-refractory locally advanced or metastatic solid tumours were reported today at the ESMO 2016 Congress in Copenhagen. [More]
Immunotherapy redefines treatment approach for metastatic bladder cancer patients

Immunotherapy redefines treatment approach for metastatic bladder cancer patients

Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen. [More]
Study reveals promising strategy against bladder cancer metastasis

Study reveals promising strategy against bladder cancer metastasis

The popular kids' card game "Exploding Kittens" teaches a concept critical to cancer science: When a player plays a "Nope" card, the subsequent player may lay another "Nope", thus creating a double-negative that becomes a positive, allowing the initial action to proceed. [More]
PD-1-responsive T cells may offer clues to design more effective drugs for cancer

PD-1-responsive T cells may offer clues to design more effective drugs for cancer

Cancer immunotherapy drugs that block the inhibitory PD-1 pathway have shown success in clinical trials and are now FDA-approved for melanoma, lung cancer and bladder cancer. Yet many patients' tumors do not respond to these drugs. [More]
Roche announces FDA approval of  new VENTANA PD-L1 assay

Roche announces FDA approval of new VENTANA PD-L1 assay

Roche today announced approval of the VENTANA PD-L1 (SP142) Assay by the US Food and Drug Administration as a complementary diagnostic to provide PD-L1 status on patients who are considering treatment with the FDA approved Roche immunotherapy TECENTRIQ™ (atezolizumab) for metastatic urothelial cancer (mUC). [More]
New Blue Light Cystoscopy with Cysview can provide accurate diagnosis of bladder tumors

New Blue Light Cystoscopy with Cysview can provide accurate diagnosis of bladder tumors

MedStar Washington Hospital Center now offers Blue Light Cystoscopy with Cysview, a new, FDA-approved technology used to pinpoint bladder tumors in patients with known or suspected bladder cancer. [More]
Certain occupations may increase bladder cancer risk, study reveals

Certain occupations may increase bladder cancer risk, study reveals

A new analysis of UK workers reveals that certain occupations may increase the risk of bladder cancer. [More]
Prognostic factor could help identify tumor recurrence after surgery for prostate cancer

Prognostic factor could help identify tumor recurrence after surgery for prostate cancer

Slightly more than 10% of all patients who undergo successful surgery for prostate cancer have an elevated risk of tumor recurrence afterwards - especially as metastases. [More]
Olive oil-based emulsion shows promise for mycobacterial treatment of bladder cancer

Olive oil-based emulsion shows promise for mycobacterial treatment of bladder cancer

Researchers at the Universitat Autònoma de Barcelona with the collaboration of the Institute for Bioengineering of Catalonia, led by the professor of the UAB Department of Genetics and Microbiology Esther Julián, announced one year ago that the cells of the Mycobacterium brumae offer an improved alternative to current bladder cancer treatments such as BCG (an immunotherapy based on the Mycobacterium bovis), which can cause infections. [More]
ERCC2 validated as chemotherapy response biomarker in bladder cancer

ERCC2 validated as chemotherapy response biomarker in bladder cancer

Somatic mutations in the helicase-encoding ERCC2 gene are associated with response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive urothelial bladder carcinoma. [More]
Study provides valuable insight into biology of tumours in early stages of cancer

Study provides valuable insight into biology of tumours in early stages of cancer

Bladder cancer is a frequent disease affecting approximately 1,900 persons in Denmark annually. A high number of these patients only have superficial tumours in the bladder when the disease is diagnosed. [More]
New analytical technology could improve cancer treatment by establishing ideal dosing regimens

New analytical technology could improve cancer treatment by establishing ideal dosing regimens

University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond. Using mass spectrometry, an analytical instrument for sensitive detection and accurate [More]
Whole-exome sequencing can help characterize genetic alterations for commonly used bladder cancer cell lines

Whole-exome sequencing can help characterize genetic alterations for commonly used bladder cancer cell lines

Much of basic cancer research is based on studies with cultured cancer cells. However, the usefulness of these studies greatly depends on how accurately these cancer cells grown in a dish represent human tumors. [More]
Advertisement